Physician profile
Rakesh Sinha
NPI 1306006358
$8,073.20
in general payments reported to CMS, 2019-2025
44 companies · $1,898 in 2025
The $1,898 reported for 2025 was more than what 75% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,180 · 2020: $522 · 2021: $795 · 2022: $1,206 · 2023: $1,220 · 2024: $1,253 · 2025: $1,898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,271 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,271.14 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,468.23 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $549.94 | 2021-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $535.69 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Merck Sharp & Dohme LLC | $498.42 | 2019-2025 | Winrevair |
| Genzyme Corporation | $461.22 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $417.02 | 2019-2025 | Ofev, Jascayd |
| Jazz Pharmaceuticals INC. | $395.24 | 2019-2023 | |
| Actelion Pharmaceuticals US, INC. | $326.81 | 2019-2025 | Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $244.82 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $239.95 | 2019-2025 | |
| Abbvie INC. | $234.16 | 2023-2025 | Avycaz |
| Philips North America LLC | $220.82 | 2019-2025 | Encore |
| Verona Pharma, INC. | $220.37 | 2025 | Ohtuvayre |
| Olympus America INC. | $215.01 | 2021-2023 | Spiration Valve System |
| Ethicon INC. | $164.02 | 2021 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $162.58 | 2021-2024 | Prolastin-C Liquid |
| Harmony Biosciences LLC | $148.79 | 2022-2025 | Wakix |
| Pulmonx Corporation | $125.00 | 2022 | |
| Insmed, INC. | $123.56 | 2021-2025 | Arikayce |
| Avadel Cns Pharmaceuticals, LLC | $115.07 | 2025 | Lumryz |
| Otsuka America Pharmaceutical, INC. | $98.08 | 2019-2024 | Rexulti, Nuedexta |
| United Therapeutics Corporation | $96.08 | 2019-2025 | Tyvaso, Orenitram, Tyvaso |
| Shionogi INC | $95.69 | 2021-2023 | Fetroja |
| Viatris Specialty LLC | $92.53 | 2025 | Yupelri |
| Melinta Therapeutics, LLC | $78.72 | 2019-2022 | |
| Davol INC. | $75.66 | 2020 | |
| Janssen Pharmaceuticals, INC | $68.46 | 2020-2022 | |
| Zoll Respicardia, INC. | $65.71 | 2023-2024 | Remede System |
| Livanova USA, INC. | $61.53 | 2022 | |
| Intuitive Surgical, INC. | $55.93 | 2023 | Da Vinci Surgical System |
| Abiomed | $54.48 | 2025 | |
| Lilly USA, LLC | $52.67 | 2025 | Zepbound |
| Allergan, INC. | $47.77 | 2019-2020 | |
| Genentech USA, INC. | $42.90 | 2019-2023 | Xolair |
| Teva Pharmaceuticals USA, INC. | $31.14 | 2023 | Austedo Xr |
| Axsome Therapeutics, INC. | $30.90 | 2023 | Sunosi |
| Mylan Specialty L.P. | $27.36 | 2023 | Yupelri |
| Gilead Sciences, INC. | $23.80 | 2022 | |
| Medtronic, INC. | $23.17 | 2021 | |
| Urovant Sciences INC | $21.78 | 2022 | |
| Advanced Respiratory, INC | $19.09 | 2019 | |
| Chiesi USA, INC. | $15.36 | 2021 | |
| Circassia INC. | $14.10 | 2020 | |
| Amgen INC. | $13.57 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rakesh Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.